Singh N N, Aman M G
Am J Ment Defic. 1981 May;85(6):580-7.
A double-blind, placebo-controlled trial of thioridazine (Mellaril) was conducted with severely retarded patients. Subjects were assessed on a relatively low standardized dose as well as on the individual dosage that had previously been determined clinically as most effective. Both active drug conditions caused a reduction in hyperactivity, bizarre behavior, and self-stimulation. The standardized dose, which was less than half the mean titrated level, resulted in an equivalent therapeutic response. The need for more attention to dosage levels in future investigations was emphasized.
对硫利达嗪（美立廉）进行了一项针对重度智力迟钝患者的双盲、安慰剂对照试验。受试者接受了相对较低的标准化剂量以及先前临床确定为最有效的个体剂量评估。两种活性药物情况均导致多动、怪异行为和自我刺激减少。标准化剂量不到平均滴定水平的一半，却产生了同等的治疗反应。强调了在未来研究中需要更多关注剂量水平。
